Johannes A Bogaards

List of Publications by Year
in descending order

68 papers	2,433 citations	257450 24 h-index	223800 46 g-index
71 all docs	71 docs citations	71 times ranked	4637 citing authors

#	Article	IF	Citations
1	Vaccine Effectiveness Following Routine Immunization With Bivalent Human Papillomavirus (HPV) Vaccine: Protection Against Incident Genital HPV Infections From a Reduced-Dosing Schedule. Journal of Infectious Diseases, 2022, 226, 634-643.	4.0	7
2	Approximate likelihoodâ€based estimation method of multipleâ€type pathogen interactions: An application to longitudinal pneumococcal carriage data. Statistics in Medicine, 2022, 41, 981-993.	1.6	1
3	Can we screen less frequently for STI among PrEP users? Assessing the effect of biannual STI screening on timing of diagnosis and transmission risk in the AMPrEP Study. Sexually Transmitted Infections, 2022, , sextrans-2022-055439.	1.9	3
4	Partial Protective Effect of Bivalent Human Papillomavirus 16/18 Vaccination Against Anogenital Warts in a Large Cohort of Dutch Primary Care Patients. Clinical Infectious Diseases, 2021, 73, 291-297.	5.8	3
5	Estimating the direct effect of human papillomavirus vaccination on the lifetime risk of screenâ€detected cervical precancer. International Journal of Cancer, 2021, 148, 320-328.	5.1	7
6	Population Impact of Girls-Only Human Papillomavirus 16/18 Vaccination in The Netherlands: Cross-Protective and Second-Order Herd Effects. Clinical Infectious Diseases, 2021, 72, e103-e111.	5.8	6
7	Risk of Cervical Intraepithelial Neoplasia Grade 3 or Worse in HPV-Positive Women with Normal Cytology and Five-Year Type Concordance: A Randomized Comparison. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 485-491.	2.5	0
8	Bivalent Vaccine Effectiveness Against Anal Human Papillomavirus Positivity Among Female Sexually Transmitted Infection Clinic Visitors in the Netherlands. Journal of Infectious Diseases, 2020, 221, 1280-1285.	4.0	7
9	The cost-effectiveness profile of sex-neutral HPV immunisation in European tender-based settings: a model-based assessment. Lancet Public Health, The, 2020, 5, e592-e603.	10.0	16
10	Evidence for Missing Positive Results for Human Papilloma Virus 45 (HPV-45) and HPV-59 with the SPF ₁₀ -DEIA-LiPA ₂₅ (Version 1) Platform Compared to Type-Specific Real-Time Quantitative PCR Assays and Impact on Vaccine Effectiveness Estimates. Journal of Clinical Microbiology, 2020, 58, .	3.9	2
11	HPV infections among young MSM visiting sexual health centers in the Netherlands: Opportunities for targeted HPV vaccination. Vaccine, 2020, 38, 3321-3329.	3.8	11
12	Human Papillomavirus Genotype Replacement: Still Too Early to Tell?. Journal of Infectious Diseases, 2020, 224, 481-491.	4.0	25
13	Pricing of HPV vaccines in European tender-based settings. European Journal of Health Economics, 2019, 20, 271-280.	2.8	18
14	Capturing multiple-type interactions into practical predictors of type replacement following human papillomavirus vaccination. Philosophical Transactions of the Royal Society B: Biological Sciences, 2019, 374, 20180298.	4.0	8
15	HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control. Papillomavirus Research (Amsterdam, Netherlands), 2019, 8, 100184.	4.5	41
16	Fast approximate computation of cervical cancer screening outcomes by a deterministic multiple-type HPV progression model. Mathematical Biosciences, 2019, 309, 92-106.	1.9	6
17	Bivalent Human Papillomavirus (HPV) Vaccine Effectiveness Correlates With Phylogenetic Distance From HPV Vaccine Types 16 and 18. Journal of Infectious Diseases, 2019, 220, 1141-1146.	4.0	32
18	Potential effectiveness of prophylactic HPV immunization for men who have sex with men in the Netherlands: A multi-model approach. PLoS Medicine, 2019, 16, e1002756.	8.4	8

#	Article	IF	Citations
19	P540â€...HPV (sero) prevalence among young MSM visiting the STI clinic: opportunities for targeted HPV vaccination. , 2019, , .		0
20	Estimating the Human Papillomavirus Genotype Attribution in Screen-detected High-grade Cervical Lesions. Epidemiology, 2019, 30, 590-596.	2.7	9
21	Assessment of herd effects among women and heterosexual men after girlsâ€only HPV16/18 vaccination in the Netherlands: A repeated crossâ€sectional study. International Journal of Cancer, 2019, 144, 2718-2727.	5.1	13
22	Who Will Benefit From Expanding HPV Vaccination Programs to Boys?. JNCI Cancer Spectrum, 2018, 2, pky076.	2.9	7
23	Ten years of HPV vaccination in the Netherlands: current evidence and future challenges in HPV-related disease prevention. Expert Review of Vaccines, 2018, 17, 1093-1104.	4.4	11
24	Inferring Pathogen Type Interactions Using Cross-sectional Prevalence Data. Epidemiology, 2018, 29, 666-674.	2.7	14
25	Bivalent Vaccine Effectiveness Against Type-Specific HPV Positivity: Evidence for Cross-Protection Against Oncogenic Types Among Dutch STI Clinic Visitors. Journal of Infectious Diseases, 2018, 217, 213-222.	4.0	72
26	Disease burden of human papillomavirus infection in the Netherlands, 1989â€"2014: the gap between females and males is diminishing. Cancer Causes and Control, 2017, 28, 203-214.	1.8	22
27	No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors. Journal of Infection, 2017, 74, 393-400.	3.3	19
28	Health and Economic Impact of a Tender-Based, Sex-Neutral Human Papillomavirus 16/18 Vaccination Program in the Netherlands. Journal of Infectious Diseases, 2017, 216, 210-219.	4.0	26
29	What explains anorectal chlamydia infection in women? Implications of a mathematical model for test and treatment strategies. Sexually Transmitted Infections, 2017, 93, 270-275.	1.9	43
30	The whole story: a systematic review of economic evaluations of HPV vaccination including non-cervical HPV-associated diseases. Expert Review of Vaccines, 2017, 16, 361-375.	4.4	16
31	A Bivariate Mixture Model for Natural Antibody Levels to Human Papillomavirus Types 16 and 18: Baseline Estimates for Monitoring the Herd Effects of Immunization. PLoS ONE, 2016, 11, e0161109.	2.5	10
32	Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Public Health, The, 2016, 1, e8-e17.	10.0	210
33	An exploration of individual- and population-level impact of the 2-dose HPV vaccination schedule in pre-adolescent girls. Human Vaccines and Immunotherapeutics, 2016, 12, 1381-1393.	3.3	13
34	Incidence and persistence of carcinogenic genital human papillomavirus infections in young women with or without <i>Chlamydia trachomatis</i> coâ€infection. Cancer Medicine, 2015, 4, 1589-1598.	2.8	45
35	Primary human papillomavirus DNA screening for cervical cancer prevention: Can the screening interval be safely extended?. International Journal of Cancer, 2015, 137, 420-427.	5.1	21
36	Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: bayesian evidence synthesis. BMJ, The, 2015, 350, h2016-h2016.	6.0	75

#	Article	IF	Citations
37	Inconclusive evidence for non-inferior immunogenicity of two- compared with three-dose HPV immunization schedules in preadolescent girls: A systematic review and meta-analysis. Journal of Infection, 2015, 71, 61-73.	3.3	27
38	Estimating Seroprevalence of Human Papillomavirus Type 16 Using a Mixture Model with Smoothed Age-dependent Mixing Proportions. Epidemiology, 2015, 26, 8-16.	2.7	18
39	Population- and Type-Specific Clustering of Multiple HPV Types Across Diverse Risk Populations in the Netherlands. American Journal of Epidemiology, 2014, 179, 1236-1246.	3.4	25
40	Rectal Swabs for Analysis of the Intestinal Microbiota. PLoS ONE, 2014, 9, e101344.	2.5	117
41	Association between human papillomavirus vaccine uptake and cervical cancer screening in the Netherlands: Implications for future impact on prevention. International Journal of Cancer, 2013, 132, 932-943.	5.1	26
42	Cost-Effectiveness of Cervical Cancer Prevention in Central and Eastern Europe and Central Asia. Vaccine, 2013, 31, H71-H79.	3.8	18
43	Clinical Progression of High-Grade Cervical Intraepithelial Neoplasia: Estimating the Time to Preclinical Cervical Cancer From Doubly Censored National Registry Data. American Journal of Epidemiology, 2013, 178, 1161-1169.	3.4	100
44	Seroepidemiology of High-Risk HPV in HIV-Negative and HIV-Infected MSM: The H2M Study. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1698-1708.	2.5	31
45	Patterns of Human Papillomavirus DNA and Antibody Positivity in Young Males and Females, Suggesting a Site-Specific Natural Course of Infection. PLoS ONE, 2013, 8, e60696.	2.5	40
46	Impact of vaccine protection against multiple HPV types on the cost-effectiveness of cervical screening. Vaccine, 2012, 30, 1813-1822.	3.8	26
47	The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands. Vaccine, 2011, 29, 8929-8936.	3.8	25
48	Assessment of herd immunity from human papillomavirus vaccination. Lancet Infectious Diseases, The, 2011, 11, 896.	9.1	5
49	Long-term Impact of Human Papillomavirus Vaccination on Infection Rates, Cervical Abnormalities, and Cancer Incidence. Epidemiology, 2011, 22, 505-515.	2.7	62
50	Sex-Specific Immunization for Sexually Transmitted Infections Such as Human Papillomavirus: Insights from Mathematical Models. PLoS Medicine, 2011, 8, e1001147.	8.4	52
51	Prevalence of carriage of meticillin-susceptible and meticillin-resistant Staphylococcus aureus in employees of five microbiology laboratories in The Netherlands. Journal of Hospital Infection, 2010, 74, 292-294.	2.9	8
52	The health and economic effects of HPV DNA screening in The Netherlands. International Journal of Cancer, 2010, 127, 2147-2158.	5.1	53
53	Evaluating the performance of survey-based operational management procedures. Aquatic Living Resources, 2010, 23, 77-94.	1.2	9
54	Model-Based Estimation of Viral Transmissibility and Infection-Induced Resistance From the Age-Dependent Prevalence of Infection for 14 High-Risk Types of Human Papillomavirus. American Journal of Epidemiology, 2010, 171, 817-825.	3.4	66

#	Article	IF	Citations
55	ISâ€pro: highâ€throughput molecular fingerprinting of the intestinal microbiota. FASEB Journal, 2010, 24, 4556-4564.	0.5	82
56	Vaccination against human papillomavirus types 16 and 18: the impact on cervical cancer. Future Oncology, 2010, 6, 1817-1821.	2.4	3
57	Individual quotas, fishing effort allocation, and over-quota discarding in mixed fisheries. ICES Journal of Marine Science, 2010, 67, 323-333.	2.5	102
58	Enrichment Broth Improved Detection of Extended-Spectrum-Beta-Lactamase-Producing Bacteria in Throat and Rectal Surveillance Cultures of Samples from Patients in Intensive Care Units. Journal of Clinical Microbiology, 2009, 47, 1885-1887.	3.9	45
59	Bayesian survey-based assessment of North Sea plaice (Pleuronectes platessa): extracting integrated signals from multiple surveys. ICES Journal of Marine Science, 2009, 66, 665-679.	2.5	8
60	The potential of targeted antibody prophylaxis in SARS outbreak control: A mathematic analysis. Travel Medicine and Infectious Disease, 2007, 5, 70-78.	3.0	2
61	Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants. PLoS Medicine, 2006, 3, e237.	8.4	594
62	Plasma HIV-1 RNA to Guide Patient Selection for Antiretroviral Therapy in Resource-Poor Settings. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 41, 232-237.	2.1	3
63	Is population-level perversity a likely outcome of mass vaccination against HIV?. Lancet Infectious Diseases, The, 2005, 5, 254.	9.1	2
64	Meeting the immense need for HAART in resource-poor settings. Journal of Antimicrobial Chemotherapy, 2003, 52, 743-746.	3.0	7
65	AIDS Vaccines That Allow HIV-1 to Infect and Escape Immunologic Control. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 34, 214-220.	2.1	18
66	Low versus high CD4 cell count as starting point for introduction of antiretroviral treatment in resource-poor settings: a scenario-based analysis. Antiviral Therapy, 2003, 8, 43-50.	1.0	1
67	Low versus High CD4 Cell Count as Starting Point for Introduction of Antiretroviral Treatment in Resource-Poor Settings: A Scenario-Based Analysis. Antiviral Therapy, 2003, 8, 43-50.	1.0	7
68	Naturally HIV-1 seroconverters with lowest viral load have best prognosis, but in time lose control of viraemia. Aids, 2002, 16, 791-793.	2.2	24